AspenBio Pharma to Present at the Roth Capital Partners 19th Annual Conference
Presentation to Include the Recently Released Positive Results from Preliminary Clinical Trials of the Company’s Appyscore™ and Appyscreen™, Being Developed as the World’s First and Only Blood-Based Tests for Human Appendicitis
CASTLE ROCK, CO—February 1, 2007—AspenBio Pharma, Inc. (OTC Bulletin Board: APNB:OB) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the Roth Capital Partners 19th Annual Orange County Stock Conference, scheduled for February 19-22, 2007 at the Ritz Carlton in Laguna Niguel, California.
AspenBio Pharma president and CEO, Richard Donnelly, is scheduled to present on Thursday, February 22nd, at 12:30 PM Pacific. A simultaneous Webcast will be available at http://www.wsw.com/webcast/roth9/apnb.ob.
The presentation will discuss the development status of the company’s human appendicitis blood test and positive results from preliminary clinical trials as recently announced on January 16th. AspenBio has created and optimized a specialized assay test to detect a marker in the blood associated with appendicitis and has tested this assay in several on-going research trials involving hundreds of human patients. The recently disclosed AppyScore and AppyScreen tests are designed to address the need for a faster, more accurate, and more economical assessment of the appendicitis condition, and are anticipated to be the first and only such tests available.
The company anticipates a third quarter 2007 regulatory filing with the FDA. The FDA approval process for diagnostic tests is typically much shorter than for drugs, and if successfully completed and approved, management’s estimates suggest a worldwide, several hundred million dollar market potential.
Roth Capital Partners Stock Conferences are one of the largest in the nation for micro and small-cap companies in the Technology, Healthcare, Financial Services, and Consumer Products sectors. For more information on the conference, please visit the conference website at http://rothconference.com, or call the conference desk at 800-678-9147.
About Roth Capital Partners, LLC
Since 1984, Roth Capital Partners has been a leader and innovator in the small and micro cap markets. With headquarters in Newport Beach, California and offices in strategic locations in the Western United States, Roth Capital Partners is a full service investment bank serving corporate and institutional clients throughout the world. Roth offers a wide array of investment banking services including: initial public offerings, follow-ons, PIPEs, private placements, mergers and acquisitions, investment research, and institutional sales and trading. The firm is perhaps best known for finding, funding and fostering the growth of emerging companies. Over the last ten years, Roth has raised more than $8.7 billion for small and micro cap public companies and completed more than 123 merger, acquisition and advisory assignments. It is a member of the National Association of Securities Dealers (NASD), and the Securities Investor Protection Corporation (SIPC). For more information, visit www.rothcp.com.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to make exciting progress in the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, please visit: www.aspenbiopharma.com.
For more information contact:
AspenBio Pharma, Inc.
Gregory Pusey, Chairman
303-722-4008
Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
949-574-3860
